Cannabis Medical Rescheduling to Schedule III: What It Really Means (Updated)

The federal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA) is a significant — but widely misunderstood — policy shift. As of April 2026, the process is still ongoing: President Trump signed Executive Order 14370 in December 2025, directing the DEA to expedite rescheduling; the DEA issued a Notice of Proposed Rulemaking in February 2026, the public comment period closed April 15, 2026, and a final rule is not expected until late 2026 or early 2027 at the earliest. For now, only medical cannabis will be able to take advantage of Schedule III benefits over normal business owners still operating under Schedule I

The core message: Schedule III is not legalization. It is a federal reclassification that changes the government's official stance on cannabis's medical value and abuse potential — and most critically, eliminates the punishing 280E tax burden — but leaves the broader legal landscape for state-licensed cannabis businesses largely intact.

Where the Process Stands in April 2026

The rescheduling process has moved faster under Trump's executive order, but multiple procedural and legal hurdles remain:

• December 18, 2025: EO 14370 signed, directing expedited rescheduling

• February 1, 2026: DEA issued Notice of Proposed Rulemaking

• April 15, 2026: Public comment period closed (~40,000 submissions)

• April 23, 2026: President Trump reclassifies only Medical Cannabis companies.

• June 29, 2026: an expedited administrative hearing will begin to consider broader rescheduling from Schedule I to Schedule III, in addition to big medical.

An interlocutory appeal that had previously stalled the DEA hearing process appears to have been resolved by Trump's executive order and the new proposed rulemaking, but additional legal challenges from parties opposed to rescheduling remain possible.

Under the Congressional Review Act, once a final rule is published, Congress has a 60-day window to pass a resolution of disapproval. Given current political dynamics, this is considered unlikely — but it represents one more procedural layer before rescheduling becomes fully effective.

What the Schedules Actually Mean

Under the Controlled Substances Act, all controlled substances are placed into one of five schedules based on two factors: accepted medical use and potential for abuse or dependence.

Schedule	Medical Use	Abuse Potential	Examples
I (current)	None accepted	High	Heroin, LSD, MDMA
II	Accepted	High	Cocaine, fentanyl, methamphetamine
III (proposed)	Accepted	Moderate-to-low	Ketamine, anabolic steroids, Tylenol w/ codeine
IV	Accepted	Lower than III	Xanax, Valium, Ambien
V	Accepted	Lowest	Cough syrups with codeine

Moving cannabis to Schedule III means the federal government formally acknowledges it has accepted medical use and moderate-to-low dependence potential — a dramatic shift from 50+ years of Schedule I status alongside heroin. The rescheduling was supported by scientific and medical evaluation from HHS, with the National Institute on Drug Abuse concurring in the recommendation.

What Actually Changes

The 280E Tax Relief — The Biggest Deal

This is the single most consequential change for cannabis operators. Under Internal Revenue Code Section 280E — enacted in 1982 — any business "trafficking" in Schedule I or II substances is prohibited from deducting ordinary and necessary business expenses on federal taxes.

The practical impact is brutal: cannabis operators pay federal income tax on gross income rather than net profit. While the cost of goods sold (COGS) remains deductible, expenses like payroll, rent, marketing, insurance, utilities, and professional services are not. The result is effective federal tax rates that routinely exceed 70% for cannabis businesses — versus the ~21% corporate rate other industries pay.

Because 280E only applies to Schedule I and II substances, rescheduling to Schedule III removes cannabis from 280E's scope entirely. Once effective, cannabis operators could:

• Deduct ordinary and necessary business expenses (payroll, rent, marketing, insurance)

• Access standard business tax credits

• Report net income instead of gross income for federal tax purposes

• Align their effective tax rates with those of other legitimate industries

Industry experts describe this as potentially "the difference between survival and investment" for plant-touching operators. For a microbusiness or mezzobusiness running on thin margins, the cash flow improvement could be transformational. It's worth noting that some tax professionals believe the government may attempt to find alternative ways to retain 280E-level tax revenue from the cannabis industry, though this is speculative.

One important timing note: 280E relief would apply beginning in the tax year the final rule takes effect — not retroactively. Operators should not amend prior-year returns preemptively.

Enhanced Research Opportunities

Schedule I status has been the primary reason U.S. cannabis research has lagged behind other countries. Under Schedule I, researchers face extraordinary DEA licensing requirements, limited supply access, and institutional reluctance to fund studies.

Schedule III meaningfully lowers these barriers. It opens pathways for universities, biotech companies, and pharmaceutical firms to study cannabis-derived compounds under standard drug development models — including expanded clinical trials, licensing agreements, and institutional investment in cannabinoid therapeutics. The Trump executive order specifically emphasized facilitating medical research and CBD access as core goals.

This is likely a bigger win for Big Pharma than for state-licensed dispensaries — companies with the resources for FDA approval processes stand to benefit most from a more permissive research environment.

Reduced Stigma and Investor Confidence

A formal federal acknowledgment of cannabis's medical legitimacy lowers perceived legal and compliance barriers for many financial institutions and institutional investors who were previously sidelined by Schedule I. This means:

• More willingness from banks to engage with cannabis businesses (even if not guaranteed)

• Exchanges are becoming more receptive to cannabis company listings

• Traditional institutional investors re-entering the space

• Improved valuations and M&A activity as the industry becomes "less toxic" to mainstream capital

Some Criminal Penalty Reduction

Schedule I carries certain unique criminal penalties and advertising restrictions that would no longer apply under Schedule III. However, this is narrower than it sounds — many CSA provisions specifically target marijuana regardless of its schedule, and most criminal penalties remain intact. Prior convictions are not affected by rescheduling.

What Does NOT Change

This is where widespread public confusion occurs. Here is what Schedule III does not do:

State-Licensed Cannabis Remains Federally Illegal

The most important misunderstanding: rescheduling does not make state-licensed dispensary sales federally legal. Cannabis businesses — including Minnesota microbusinesses, mezzobusinesses, and retailers — would still be operating outside any federal licensing framework. The DEA could theoretically still enforce federal law against state-legal operators.

No Interstate Commerce

Interstate cannabis sales remain prohibited. Under Schedule III, interstate commerce is limited to FDA-approved drugs. State-licensed cannabis products are not FDA-approved medications. Moving product across state lines remains a federal crime.

Banking Access Remains Limited for Small/Medium Non-Medical Businesses

Schedule III does not resolve the fundamental banking problem. Banks remain exposed to potential money laundering charges, loss of FDIC insurance, and regulatory action for processing proceeds from cannabis sales — because the underlying activity is still federally illegal outside FDA-approved channels. The SAFER Banking Act, which would provide an explicit federal safe harbor for banks serving state-legal cannabis businesses, remains the clearest path to meaningful banking reform — and it has not passed.

What may improve: some smaller banks and credit unions operating under state jurisdiction, payment processors, and alternative financial services may become slightly more willing to serve cannabis clients as compliance risk perception decreases. ACH payment systems are already seeing increased adoption — nearly 42% of cannabis transactions are projected to run on ACH rails in 2026, up from 28% in 2025. But Schedule III alone does not open the floodgates.

Credit Cards Still Off-Limits

Card network rules (Visa, Mastercard) prohibit credit card acceptance for plant-touching cannabis businesses regardless of federal scheduling. This is a card network policy issue, not solely a federal law issue.

Doctors Still Cannot "Prescribe" Cannabis

Federal prescriptions require FDA-approved drugs dispensed through DEA-registered pharmacies. Cannabis products sold in state dispensaries are not FDA-approved. Medical access remains certification-based under state law. Patients cannot take a federal prescription to a state dispensary as things stand.

Federal Benefits and Employment Restrictions Remain

Federal housing assistance, federal employment background checks, firearm purchasing questions (ATF Form 4473), and other federal benefit restrictions tied to drug use remain largely intact. Unprescribed recreational use remains federally illegal.

No Effect on State Law

Rescheduling does not affect state cannabis laws — in either direction. States with adult-use markets (like Minnesota) remain fully operative under state authority. States that ban cannabis remain free to do so.

The FDA Regulatory Wild Card

One underappreciated complexity: Schedule III activates FDA regulatory authority in a way that was largely dormant under Schedule I. The FDA published guidance in March 2026 outlining how it would regulate cannabis products under Schedule III, including pathways for pharmaceutical cannabis products.

This creates a significant open question for the state-licensed industry: will the FDA begin treating cannabis like other Schedule III drugs, requiring manufacturers and retailers to hold DEA licenses and requiring products to undergo the FDA approval process before being marketed? If so, this could create a massive compliance burden for the existing industry.

Current FDA-approved cannabinoid products — Epidiolex (CBD for seizures), Marinol/Syndros, and Cesamet — all went through the full FDA approval process and are only available by prescription through licensed pharmacies. The FDA has historically maintained that cannabinoids cannot be added to foods or marketed as dietary supplements where the active ingredient has already been approved as a drug, and Schedule III does not resolve this conflict.

The most likely outcome is a two-track system: FDA-approved pharmaceutical cannabinoids on one track, and state-regulated products on another track that the federal government tolerates without formally authorizing. But the boundaries of that tolerance remain undefined.

Implications for Minnesota Cannabis Operators

For Minnesota microbusiness and mezzobusiness operators, the practical near-term implications break down as follows:

Area	Impact When Final	Timeline
280E tax relief	High — deduct payroll, rent, marketing, etc.	Tax year final rule takes effect
Banking access	Low-to-moderate — SAFER Banking Act still needed	Uncertain
State licensing/operations	None — OCM rules unchanged	N/A
Interstate commerce	None — still prohibited	N/A
Capital access/investment	Moderate — reduced stigma for investors	Gradual, ongoing
Research pathways	Moderate — benefits larger operations/pharma more	Gradual, ongoing
Criminal risk	Slight reduction in some penalties	When final rule effective

The most actionable preparation for operators right now:

• Work with a CPA familiar with cannabis tax law to model the impact of 280E relief on your specific cost structure and prepare for the transition once a final rule is effective

• Do not restructure operations prematurely based on an unfinalized rule — the final rule could face further delays or legal challenges

• Monitor the SAFER Banking Act progress separately, as banking reform is the bigger operational unlock for daily operations. Or just have us do it.

• Understand that your state licenses and compliance requirements are unchanged — OCM rules are the governing framework, regardless of federal scheduling